A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors (Annals of Oncology, 2016)

(untitled) - Pacey, S; Blackhall, F; Garcia-Corbacho, J; Lipplaa, A; Fusi, A; Kumar, S; Hategan, M; Derham, J; Laviste, G; Halford, S; Foxton, C; McLeod, R; et al.